Atossa Therapeutics, Inc. (ATOS)

NASDAQ: ATOS · IEX Real-Time Price · USD
0.803
+0.002 (0.21%)
Feb 1, 2023, 10:29 AM EST - Market open
0.21%
Market Cap 101.62M
Revenue (ttm) n/a
Net Income (ttm) -24.30M
Shares Out 126.62M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 94,963
Open 0.820
Previous Close 0.801
Day's Range 0.787 - 0.820
52-Week Range 0.500 - 1.620
Beta 1.13
Analysts Buy
Price Target 5.10 (+535.51%)
Earnings Date Feb 27, 2023

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-1... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 8, 2012
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ATOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 535.51% from the latest price.

Price Target
$5.1
(535.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

The 3 Best Biotech Stocks Under $1 to Buy for January

While biotech may be the next big thing, making money through it isn't easy. Indeed, investing in biotech stocks is often more of an art than a science.

Other symbols: SPPIVCNX
5 days ago - InvestorPlace

Atossa Therapeutics Issues Letter to Shareholders

SEATTLE, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet...

1 week ago - GlobeNewsWire

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

SEATTLE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical ne...

2 months ago - GlobeNewsWire

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), today announces financial results for the fiscal quarter ended September 30, 2022, and provides an update on recent...

3 months ago - GlobeNewsWire

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (...

3 months ago - GlobeNewsWire

Atos returns to sales growth in Q3, beats market expectations

France's Atos said on Wednesday its sales returned to growth in the third quarter, beating expectations as the loss-making IT consulting firm strives to regain markets' trust by carrying out a costly ...

3 months ago - Reuters

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molecule/targeted therapies for hematology-oncology diseases Oversaw FDA approval of CAR-T/CAR-NK cell therapy, ADCs, and small molec...

3 months ago - GlobeNewsWire

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter Atossa to begin Phase 2 Study of (Z)-endoxifen in 4th Quarter

3 months ago - GlobeNewsWire

Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet m...

5 months ago - GlobeNewsWire

Registration Now Open for Tribe Public's Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022

Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO Meet with Atossa's CEO & Founder, Dr. Steven Quay, M.D., Ph.D. & Kyle Guse, GC & CFO

5 months ago - GlobeNewsWire

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina The Company Re-Appoints Drs. Mak Jawadekar, Per Hall, and Carl Novina

5 months ago - GlobeNewsWire

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infe...

6 months ago - GlobeNewsWire

Dosing Completed in Part C of Atossa's Phase 1/2a Study of AT-H201 in Healthy Volunteers

Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment Atossa Plans to Initiate a New Development Path in Patients with Compromised ...

6 months ago - GlobeNewsWire

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of signific...

8 months ago - GlobeNewsWire

Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significa...

9 months ago - GlobeNewsWire

Atossa Therapeutics to Present at the Q2 Investor Summit Conference

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet m...

10 months ago - GlobeNewsWire

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE

10 months ago - GlobeNewsWire

Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference

SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

11 months ago - GlobeNewsWire

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

11 months ago - GlobeNewsWire

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) --  Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious dise...

1 year ago - GlobeNewsWire

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet me...

1 year ago - GlobeNewsWire

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Nebulized Formulation Being Developed to Improve Lung Function in Both Active-disease COVID-19 Patients and “Long Haul” Patients With Post-Infection Pulmonary Disease Nebulized Formulation Being Devel...

1 year ago - GlobeNewsWire

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

SEATTLE, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet med...

1 year ago - GlobeNewsWire

Physician-Scientist Steven Quay Calls for International Effort to Investigate a Coronavirus discovered in Laos by Institut Pasteur

SEATTLE, Dec. 16, 2021 /PRNewswire/ -- Physician-Scientist Steven Quay, MD, PhD has published an e-print on his research into a new coronavirus, named BANAL-236, reported by the Institut Pasteur in Se...

1 year ago - PRNewsWire

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting Input Received on Pathway for Proprietary Z-Endoxifen to Treat Breast Cancer in Neoadjuvant Setting

1 year ago - GlobeNewsWire